This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Biotech Showcase is true to its name – great companies are highlighted.” Tina Elder, Global Managing Director, EBD Group US, said, “Biotech Showcase has once again shown itself to be the premiere destination for innovators and partners to access a powerful network of industry decision-makers, media and top investors.
The acquisition immediately expands EVERSANA’s European operations and worldwide capabilities to help pharmaceutical, medical device, and emerging biotech companies globally launch products, expand market access, or solve unique geographic and market-specific challenges.
The following is a guest article by Steve Lazer, Global Healthcare & LifeSciences CTO at Dell Technologies. One rapidly advancing trend in healthcare and lifesciences is the shift from inefficient, expensive physical models to digital models tested in the virtual world.
As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. We look for similar customer-oriented ethos and patient-centric mindsets in our partnerships,” said Kim Kushner, Chief Business Officer, SSI Strategy. Learn more at koneksahealth.com.
The following is a guest article by Steve Lazer, Global Healthcare & LifeSciences CTO at Dell Technologies. The primary use cases for cognitive AI in biotech include accelerating data analysis, automating document management, improving collaboration, and reducing risk of human error.
With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the lifesciences and healthcare sector. Please visit astrazeneca.com and follow the Company on Social Media @ AstraZeneca.
.–(BUSINESS WIRE)–BIOQuébec and BioFlorida, preeminent lifesciences associations from Québec and Florida, are proud to announce the signing of a Memorandum of Understanding (MOU). Fostering global connections and innovation and fueling growth are key to advancing the lifesciences industry in Florida,” said Nancy K.
EVERSANA INTOUCH Healthware joins five full-service affiliates and four specialty affiliates serving clients across the globe with world-class strategy, next-generation branding and creative, and innovative solutions to propel the future of lifescience marketing. They are, however, fully owned and operated by EVERSANA.
Supreme Group is a healthcare commercialization platform company formed following Trinity Hunt’s majority investment in Supreme Optimization , a leading lifescience-focused digital agency. We look forward to supporting the agency as it continues on its growth trajectory.” Health+Commerce has been named an Inc.
Accenture announced it has made a strategic investment, through Accenture Ventures , in QuantHealth , an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients. Petra Jantzer, Ph.D.,
Strategies for assessing data completeness and developing signal quality indices, as demonstrated for example in epilepsy studies, contribute to enhancing the credibility of DHT-derived measures. AstraZeneca has launched Evinova , an healthtech business focusing on providing digital solutions for clinical trials in the lifesciences sector.
QuantHealth proudly supports several large pharma companies, numerous biotechs, as well as CROs, and other industry partners. market , along with a series of executive appointments including David Dornstreich as Chief Commercial Officer and Co-Founder Arnon Horev as Chief Strategy and Operations Officer.
Edelman’s health industry segments for this study are pharma, consumer health, insurance, biotech/lifescience, and hospitals. Consumer health went opposite, up 7 points, biotech up 3, insurance up 8, pharma up 6. consumer trust across all of these segments increased a bit – except for hospitals, which fell 7 points.
Jane Reed, Director of LifeSciences at Linguamatics, an IQVIA company Pharmaceutical developers have always prioritized drug safety. Pouria Sanae, CEO at ixlayer In 2024 we can expect care teams to get bigger, broader, and more collaborative as new digital tools and care strategies combine to shift the status quo.
Founded in 2018 and supported from the outset by LallianSe, the lifesciences integrator, BrainTale has developed and commercializes an accessible, reliable and clinically validated brain measurement digital platform solution for drug developers and physicians – neurologists, neuroradiologists and intensivists.
About RA Capital Management RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and lifescience companies that are developing drugs, medical devices, and diagnostics. For more information, please visit www.rac a p.com. Find out more: www.sanofiventures.com.
Global marketing strategy and marketing consulting firm Simon-Kucher & Partners surveyed more than 120 managers from the pharma and medtech industries in August and September of this year to […].
It is also worth noting that Scotland's healthtech ecosystem is well-supported by a number of government and industry initiatives, such as the Scottish National Health Service (NHS) Scotland Health Innovation Hub and the LifeSciences Scotland industry body. The company raised $10m in 2022.
This commitment has resulted in a national digital health strategy and the creation of the Digital Health & Care Innovation Centre (DHI), which supports collaboration and innovation in the sector. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors.
The press release lists the names of each of the 47 individual pharma companies assessed, such as Big Pharma leaders like AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, Novartis, and Pfizer, along with companies associated with biotech like Amgen, Biogen, Genentech, and Gilead. Gilead Science, and. Roche/Genentech.
The seed round was co-led by Wellington Partners and Forbion and includes non-dilutive financing from BMBF GO-Bio, a prestigious German government initiative aimed at supporting the most innovative startups in the lifesciences. Forbion invests in lifesciences companies that are active in the (bio) pharmaceutical space.
Investment Marks a Significant Milestone in Advancing AI-Based Arrhythmia Care SAN DIEGO–(BUSINESS WIRE)– Vektor Medical , a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced a $16 million Series A investment co-led by Solas BioVentures and TVM Capital LifeScience. Solas puts patients first.
BPS has long been recognized worldwide as a trusted and preferred partner of contract manufacturing services for the pharmaceutical and biotech industries. BPS has been a leading provider of sterile contract manufacturing solutions, parenteral delivery systems and customized support services to the pharma and biotech industries for decades.
Jesse Cugliotta, Global Industry GTM Lead, Healthcare & LifeSciences at Snowflake. One of the core issues is that the industry has become single threaded in its sourcing strategy. The new year will bear witness to great innovation in biotech in the precision oncology space. Dr. Ofer Sharon, CEO at OncoHost.
Here’s one of many looks into the issue , in which I’m quoted on scenarios for Gilead’s possible pricing strategies for remdesivir. In today’s pharma/biotech market, the “specialty” label is given to many therapies: for products addressing rare diseases, risk-management, and above all, high cost drugs.
Technology, biotech, hospitals, and lifescience companies would be the health care improvers, most Americans told RealClear pollsters. Ironically, Big Tech like Amazon, Apple, Google and Microsoft are all members of that Fortune 500 cohort which ranked at the bottom of this list.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content